VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

被引：10

作者：

Hochmair, M. J. ^{[1
]}

Vermaelen, K. ^{[2
]}

Mountzios, G. ^{[3
,4
]}

Carcereny, E. ^{[5
]}

Dooms, C. ^{[6
]}

Lee, S. -h. ^{[7
]}

Morocz, E. M. ^{[8
]}

Kato, T. ^{[9
]}

Ciuleanu, T-e. ^{[10
]}

Dy, G. ^{[11
]}

Parente, M. B. M. C. S. ^{[12
]}

O'Byrne, K. J. ^{[13
]}

Chu, Q. s -c. ^{[14
]}

De Castro Jr, G. ^{[14
]}

Girard, N. ^{[15
]}

Snyder, W. ^{[16
]}

Tran, Q. ^{[16
]}

Kormany, W. ^{[16
]}

Houk, B. ^{[16
]}

Curioni-Fontecedro, A. ^{[17
]}

机构：

[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Florisdorf, Vienna, Austria

[2] UZ Gent Univ Ziekenhuis Gent, Dept Pulm Med, Ghent, Belgium

[3] Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece

[4] Henry Dunant Hosp Ctr, Clin Trials Unit, Athens, Greece

[5] Catalan Inst Oncol Badalona, Badalona Appl Res Grp Oncol, Med Oncol, Badalona, Spain

[6] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium

[7] Sungkyunkwan Univ, Samsung Med Ctr SMC, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea

[8] Pest Cty Hosp Pulmonol, Pulmonolgy, Torokbalint, Hungary

[9] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Japan

[10] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania

[11] Roswell Park Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[12] CHVNG E Ctr Hosp Vila Nova Gaia Espinho, Unidade 1, Pulmonol, EPE SNS, Porto, Portugal

[13] Princess Alexandra Hosp, Canc Serv, Metro South Hlth, Woolloongabba, Qld, Australia

[14] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Thorax Inst, Inst Curie, Paris, France

[16] Amgen Inc, Oncol, Thousand Oaks, CA USA

[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 01期

关键词：

D O I：

10.1016/j.annonc.2023.10.790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：142 / 144

页数：3

共 50 条

[1] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
Hochmair, Maximilian J.
Vermaelen, Karim
Mountzios, Giannis
Carcereny, Enric
Dooms, Christophe
Lee, Se-Hoon
Morocz, Eva
Kato, Terufumi
Ciuleanu, Tudor-Eliade
Dy, Grace K.
Parente, Barbara
O'Byrne, Kenneth J.
Chu, Quincy S.
De Castro Junior, Gilberto
Girard, Nicolas
Snyder, Wendy
Tran, Qui
Kormany, William
Houk, Brett
Mehta, Bhakti
Curioni-Fontecedro, Alessandra
EUROPEAN JOURNAL OF CANCER, 2024, 208
[2] Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
Waterhouse, David M.
Rothschild, Sacha
Dooms, Christophe
Mennecier, Bertrand
Bozorgmehr, Farastuk
Majem, Margarita
Heuvel, Michel H. van den
Linardou, Helena
Cho, Byoung Chul
Roberts-Thomson, Rachel
Tanaka, Kentaro
Blais, Normand
Schvartsman, Gustavo
Hansen, Karin Holmskov
Chmielewska, Izabela
Forster, Martin D.
Giannopoulou, Christina
Stollenwerk, Bjorn
Obiozor, Cynthia C.
Wang, Yang
Novello, Silvia
LUNG CANCER, 2024, 196
[3] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
Barot, Hasti
Evans, Joanne
Mohammed, Waleed
Power, Danielle
LUNG CANCER, 2022, 165 : S77 - S77
[4] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
Jiang, Yanfang
Zhang, Lei
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
[5] Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Gadgeel, S.
Rahman, A.
Osaghae, U.
Fernando, T. M.
Lin, M. T.
Koli, K.
Meyenberg, C.
Mathisen, M.
Skoulidis, F.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S349 - S349
[6] Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial
Li, Bob T.
Clarke, Jeffrey Melson
Felip, Enriqueta
Ruffinelli, Jose Carlos
Garrido, Pilar
Zugazagoitia, Jon
Goldberg, Sarah B.
Ramalingam, Suresh S.
Victoria, Ivan
Puri, Sonam
Gandara, David R.
Kormany, William
Edmonds, Sophie
Palmer, Kerry
Gupta, Ravi G.
Govindan, Ramaswamy
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
Eser, Metin
Hekimoglu, Gulam
Yarar, Murat Hakki
Canbek, Sezin
Ozcelik, Melike
SCIENTIFIC REPORTS, 2024, 14 (01):
[8] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
Reactions Weekly, 2025, 2045 (1) : 6 - 6
[9] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, Tony Kiat Hon
Skoulidis, Ferdinandos
Kerr, Keith M.
Ahn, Myung-Ju
Kapp, Joshua R.
Soares, Fernando A.
Yatabe, Yasushi
LUNG CANCER, 2023, 184
[10] A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
Ernst, Sophie M.
von der Thusen, Jan H.
Dubbink, Hendrikus J.
Dingemans, Anne-Marie C.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09)

← 1 2 3 4 5 →